BridgeBio Pharma, Inc. (BBIO) Net margin 2019–2025
BridgeBio Pharma, Inc. (BBIO) net profit margin by fiscal year — reported net income divided by reported revenue.
-146.0%FY2025 · since FY2019: -711.5% → -146.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -146.0% | +98.9 pp |
| FY2024 | -244.9% | +6777.1 pp |
| FY2023 | -7021.9% | -6397.8 pp |
| FY2022 | -624.1% | +217.1 pp |
| FY2021 | -841.2% | +5286.7 pp |
| FY2020 | -6127.9% | -5416.4 pp |
| FY2019 | -711.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice